Glioblastoma

Psilocybin-assisted psychotherapy significantly improved a range of psychiatric symptoms among people with cancer, according to research published in Nature Mental Health.

Fear of nuclear fallout has led to a novel therapeutic approach that could significantly extend the lives of individuals with pancreatic cancer or other gastrointestinal malignancies.

The addition of high-dose IV vitamin C to standard chemotherapy nearly doubled OS for patients with advanced pancreatic cancer, according to results of a randomized phase 2 trial.

It’s only the beginning.

The addition of veliparib to adjuvant temozolomide failed to improve OS for patients with newly diagnosed, MGMT-hypermethylated glioblastoma, according to randomized phase 2/phase3 study results.

When Healio | Cell Therapy Next visited City of Hope in 2019, the institute boasted a robust cell therapy program, having treated 300 patients with the then-newly approved therapy.

Sacituzumab govitecan-hziy exhibited efficacy as therapy for two traditionally difficult-to-treat populations, according to results of a window-of-opportunity trial.

In 2018, at the height of the chimeric antigen receptor T-cell therapy revolution and in the heart of its implementation, Healio’s Cell Therapy Next staff went onsite to University of Pennsylvania’s newly minted center.

An Alabama-based company announced that the FDA has granted 510(k) clearance to its cyber device and AI system, which are designed to improve efficiency and accuracy of glioblastoma care.

Bypassing the blood-brain barrier remains an obstacle for novel therapeutics. Healio spoke to Thomas Chen, MD, PhD, founder and CEO of NeOnc, to find out how a novel nasal spray formulation to treat brain cancer overcomes these challenges.